Adherex Technologies (FENC) to Release Earnings on Monday

Adherex Technologies (NASDAQ:FENC) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Adherex Technologies to post earnings of $0.01 per share and revenue of $14.7330 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 9:30 AM ET.

Adherex Technologies Trading Down 1.4%

Shares of NASDAQ FENC opened at $8.49 on Monday. The firm has a fifty day simple moving average of $7.92 and a two-hundred day simple moving average of $8.26. Adherex Technologies has a 12 month low of $4.68 and a 12 month high of $9.92. The firm has a market capitalization of $290.53 million, a PE ratio of -36.91 and a beta of 0.75.

Insider Activity at Adherex Technologies

In other news, major shareholder Southpoint Capital Advisors Lp sold 1,000,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $7.50, for a total value of $7,500,000.00. Following the completion of the transaction, the insider owned 2,744,741 shares of the company’s stock, valued at $20,585,557.50. This represents a 26.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Rosty Raykov sold 10,349 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $7.76, for a total transaction of $80,308.24. Following the sale, the director directly owned 98,477 shares of the company’s stock, valued at approximately $764,181.52. This trade represents a 9.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,020,349 shares of company stock worth $7,655,708 in the last ninety days. Insiders own 10.98% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC purchased a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned approximately 0.05% of Adherex Technologies at the end of the most recent reporting period. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on FENC shares. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Thursday, January 22nd. Zacks Research upgraded shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a report on Friday, December 12th. Piper Sandler started coverage on shares of Adherex Technologies in a research note on Friday, January 9th. They issued an “overweight” rating and a $18.00 price target on the stock. B. Riley Financial began coverage on Adherex Technologies in a research note on Thursday, February 12th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Wall Street Zen raised shares of Adherex Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.80.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.